Anti-viral Therapeutics Market Forecast 2025 | Discover Next-Gen Antivirals & Biopharma Innovations

The Anti-Viral Therapeutics Market size was valued US$ 51.72 billion in 2021 and is estimated to reach US$70.83 billion by 2031, growing at a CAGR of 4.6% during the forecast period (2024-2031), according to DataM Intelligence. This growth is fuelled by rising demand for effective antiviral drugs, advancements in drug development technologies, and enhanced screening and diagnostic capabilities, enabling earlier detection and treatment initiation. Leading pharmaceutical companies include Gilead Sciences, Johnson & Johnson, Merck & Co., AbbVie, Bristol-Myers Squibb, Roche, Pfizer, GlaxoSmithKline, and Moderna.

Download your FREE sample report: https://www.datamintelligence.com/download-sample/anti-viral-therapeutics-market?jd

Emerging opportunities lie in the development of next-generation antivirals, including direct-acting antivirals (DAAs), RNA interference (RNAi) therapeutics, and host-targeting agents, as well as advances in biologics such as monoclonal antibodies and immunomodulators. The integration of artificial intelligence and machine learning in drug discovery and personalized antiviral regimens further drives innovation. The growth of digital health tools for patient monitoring and adherence is also enhancing therapeutic outcomes.

Influential Strategic Collaborations and Acquisitions Redefining the Anti-Viral Therapeutics Market Dynamics in 2025

1. In July 2025, Island Pharmaceuticals acquired the Galidesivir antiviral program from BioCryst Pharmaceuticals: Island fast-tracked this asset purchase agreement following due diligence for Galidesivir, a broad-spectrum antiviral effective against multiple RNA viruses, including Ebola, Marburg, MERS, and Zika. The acquisition positions Island strongly in high-priority viral threats with potential FDA approval under the Animal Rule, offering priority review vouchers valued up to $100-150 million.

2. SymBio Pharmaceuticals' portfolio expansion with brincidofovir acquisition: SymBio expanded its antiviral portfolio with rights to brincidofovir (BCV), an oral antiviral with applications against DNA viruses, demonstrating positive proof of concept in recent clinical studies. This strategic move reinforces its position in rare and difficult-to-treat viral infections.

3. Atea Pharmaceuticals advancing oral antiviral therapies: Atea, focused on oral treatments for viral diseases including COVID-19 and influenza, continues clinical development and strategic collaborations across antiviral drug candidates, increasing its pipeline and addressing unmet needs in antiviral therapeutics.

Innovative Technological Advances Driving Transformation in the Anti-Viral Therapeutics Sector in 2025

• Broad-Spectrum Antivirals and Combination Therapies: Drugs like Remdesivir, Molnupiravir, and Paxlovid (nirmatrelvir/ritonavir) became frontline treatments for SARS-CoV-2 and demonstrated the value of combination therapies targeting viral proteases and polymerases. Protease inhibitors such as Simeprevir and Paritaprevir also show antiviral activity beyond their original hepatitis C indications.

• Monoclonal Antibodies and Immunomodulators: Combinations of monoclonal antibodies (bamlanivimab/etesevimab, casirivimab/imdevimab) enhance neutralizing activity against viral variants. IL-6 inhibitors (tocilizumab, sarilumab) and Janus kinase inhibitors (baricitinib, tofacitinib) are utilized to reduce severe COVID-19 inflammation, indicating synergy between antivirals and immunomodulation.

• RNA Interference (RNAi) and Gene Editing: siRNAs and antisense oligonucleotides targeting viral genomes show promise for infections like HBV, HCV, HIV, and herpesviruses by interrupting viral replication and modulating host immune responses.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=anti-viral-therapeutics-market?jd

Prominent Regional Factors Propelling Growth Trends in the Anti-Viral Therapeutics Market by 2025

North America leads the antiviral therapeutics market with the largest share, driven by advanced healthcare infrastructure, high healthcare expenditure, widespread access to medical care, and significant investments in research and development. The U.S. has a high prevalence of viral infections such as HIV, hepatitis B and C, and influenza, fueling demand for innovative antiviral drugs including direct-acting antivirals (DAAs), protease inhibitors, and new molecules targeting emerging viruses.

Europe holds a substantial market share supported by mature healthcare systems, stringent regulatory standards, and active R&D collaborations. Countries like Germany, France, and the UK focus on tackling chronic viral infections and epidemic preparedness by advancing antiviral drug development and expanding treatment access.

Asia Pacific is the fastest-growing regional market fueled by large patient populations, rising prevalence of viral infections, expanding healthcare infrastructure, and increasing availability of generic antivirals. Countries such as China, India, Japan, and South Korea actively enhance healthcare access and invest in biopharma manufacturing capabilities.

Latin America and the Middle East & Africa represent emerging markets with growing prevalence of viral diseases such as HIV/AIDS, hepatitis, and respiratory viruses, coupled with improving healthcare infrastructure and increased government initiatives targeting viral infection control.

Request for 2 Days FREE Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg?jd

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:

DataM Intelligence is a leading Market Research and Consulting firm offering end-to-end business solutions from research to strategic consulting. At DataM Intelligence, we harness proprietary trends, insights, and industry developments to deliver swift, insightful solutions tailored to your business needs. Our extensive portfolio includes a wide range of syndicated and customized reports, built on a robust research methodology. With a database of over 6,300 reports across 40+ industries, we provide deep statistical analysis and market intelligence that supports the strategic growth of more than 200 companies in over 50 countries, addressing the critical research demands that shape their success.

This release was published on openPR.